OBB Newsletter

  • Enter your e-mail address below to subscribe to the Orange Book Blog newsletter. If a new post is added during the day, you'll receive it by e-mail the next morning.

Enter your email address:

Delivered by FeedBurner




  • Orange Book Blog is published for informational purposes only; it contains no legal advice whatsoever. Publication of Orange Book Blog does not create an attorney-client relationship. Orange Book Blog is Aaron Barkoff's personal website and it is intended for other attorneys. Orange Book Blog is not edited by McAndrews, Held & Malloy, Ltd. ("MHM") or its clients. No part of Orange Book Blog--whether information, commentary, or other--may be attributed to MHM or its clients. MHM represents many companies in the pharmaceutical and biotechnology industries, and therefore Orange Book Blog may occasionally report on news that relates to MHM clients. Orange Book Blog will always strive to be unbiased. All information on Orange Book Blog should be double-checked for its accuracy and current applicability. -- © Aaron F. Barkoff 2006-2017

« OBB News Briefs | Main | King Pharmaceuticals Files Citizen Petition Relating to New Patent on Altace (Ramipril) »

May 21, 2008



I realize the post is limited to litigation under a proposed biosimilars act, but isn't that really a peripheral issue in the whole scheme of things?

Really, the effectiveness of a biosimilars act would be (as with H-W) in permitting reference to existing safety and efficacy data, and in ultimately getting the newly approved biosimilar product readily substituted for the existing drug. Those are the most important features, as far as consumers are concerned.

Perhaps you could discuss those angles in a future post or two.

Thanks for the summary,

The comments to this entry are closed.